Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Treating insomnia with online cognitive behavioural therapy (CBT) could reduce mental health problems such as anxiety, depression, and paranoia, according to a large randomised controlled trial published today in The Lancet Psychiatry.

Image courtesy of Shutterstock

The Wellcome-funded study was conducted by researchers at the Sleep and Circadian Neuroscience Institute, University of Oxford. It found that sleep disruption is a driving factor in the occurrence of paranoia, hallucinatory experiences, and other mental health problems in young adults (university students) with an average age of 25.

The researchers aimed to improve sleep in these individuals in order to determine the effect on mental health problems such as paranoia (excessive mistrust), anxiety, and depression. 3,755 university students across the UK were randomised into two groups. One group received online cognitive behaviour therapy (CBT) for insomnia; the other group did not but had access to standard treatments.

 

Read more ....

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.